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Selective Retinoid Receptor Agonists: Tools to Understand the Function of Retinoid Receptors 
Retinoic acid receptors (RARs) and retinoid X receptors (RXRs) are 
nuclear receptors that mediate the wide-ranging biologic effects of 
retinoids. (The retinoid that binds to RXR receptors was originally 
not known but is now known to be 9-cis-retinoic acid). These 
receptors are transcription factors that affect gene expression by 
, binding to critical regions of DNA capable of initiating gene ex-
pression after the receptors are activated by retinoids. RARs and 
RXRs can combine to form a heterodimeric complex (RAR/RXR) 
that binds to target genes, and RXRs, unlike RARs can form homo-
dimers (RXR/RXR) . Unlike RXR/RAR heterodimers, however, 
RXR/RXR homodimers can only form in the presence of retinoids. 
One way to study the function of these two types of receptors is to 
use compounds that bind to either RARs or RXRs but not to both. 
This is similar to the approach used by investigators at CIRD Gal-
derma to show that RARs and not cellular retinoic acid-binding 
protein (CRAB~) ~re required for the effects of retinoids on kerati-
nocyte differentIatIon U Invest Dermatol 98:128 -134, 1992). All 
trans-retinoic acid and its stereoisomer, 9-cis-retinoic acid, activate 
RXR/ RAR heterodimers. RXR/RXR homodimers are induced 
and activated by 9-cis-retinoic acid or by a synthetic compound, 
SR11237. But unlike 9-cis-retinoic acid, SR11237 is selective and 
does not activate RXR/RAR heterodimers. In this issue, Gendi-
menico et al (p. 676) report their results using the selective ligand, 
SR 1123 7. First, they confirmed in their own experimental system 
the findings of Magnus pfahl and Marcia Dawson (Science 
258:1944 -1946, 1992) that SR11237 activates RXR but not RAR. 
In studies of the biologic effects of these retinoids, they found that a 
complex biologic response induced by all-trans-retinoic acid in F9 
embryonal cells and in rhino mouse skin cou ld not be produced by 
SRl1237. (F9 cells and mouse skin constitutively express both 
RARs and RXRs.) These studies suggest that RXR/RAR hetero-
dimers, not RXR/RXR homodimers, are responsible for this classi-
cal pleiotropic response of retinoids in biologic systems. These stud-
ies help delineate what kind of responses are produced by each 
retinoid. Such knowledge is critical in understanding how to target 
new retinoids to specific biologic pathways. 
Molecular Heterogeneity in Hepatoerythropoietic Porphyria 
Hepatoerythropoietic porphyria (HEP) is a ~are autosomal recessive 
disorder that produces severe photosensItIvIty and IS caused by 
a homozygous deficiency of uroporphyrinogen decarboxylase 
(UROD), an enzyme in the heme biosynthetic pathway that con-
verts uroporphyrinogen into coproporphyrinogen. It is known that 
there are striking differences in UROD deficiency in different pa-
tients -with the disorder. Some patients with UROD deficiency have 
immunologically undetectable enzyme, but in others it is detectable 
but inactive, and these different clinical types ofUROD deficiency 
have been found to have different mutations. (For a description of 
"cross reactive material" (CRM) positive and negative UROD mu-
rations, see Kappas et al in The Metabolic Basis oj Inherired Disease, 
Scriver et al (eds.). McGraw-Hill Book Co., 1989, pp 1305-1365). 
In this issue, Meguro et al (p. 681) report molecular analysis of 
URaD in yet another type ofHEP, involving a CRM "supernega-
tive" mutation. The patient studied had a unique discrepancy, a 
significant amount of UROD activity (- 20% normal) but an im-
munologically undetectable amount of enzyme protein in his eryth-
rocytes. To elucidate the UROD defect, the authors cloned UROD 
DNAs from the patient's cells, and analyzed their nucleotide se-
quences. They found that the patient had two separate missense 
mutations in each of his two UROD alleles; that is, the proband 
is a compo£lIId heterozygote for the UROD defect. One mutation 
was a single base transition resulting in a His220 -+ Pro change, 
whereas the other comprised three successive point mutations 
(TGT -+ CCA), but resulted only in a Val '34 -+ GIn change. De-
spite the mutation, these mutant UROD cDNAs produced signifi-
cant enzyme activity when they were trallsfected into Chinese 
hamster ovary cells and expressed, consistent with the authors' find-
in~ of significant .UROD activity in the proband's erythrocytes. 
WIth thIS report, SIX dIfferent mutations have been described to date 
in four different families with HEP (Table 1, p. 684), suggesting a 
marked heterogeneity of UROD deficiency in this disorder. It is 
also interesting to note that none of the mutations found in UROD 
deficiency in HEP has been reported in patients with familial por-
phyria cutanea tarda (fpCT) , which is caused by heterozygous 
UROD deficiency, raising the possibility that HEP is not a homo-
zygous form of fpCT. 
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How to Interpret Immunofluorescence Studies with Pemphigoid Sera 
The 230-kDa and 180-kDa bullous pemphgoid (BP) antigens, 
prominent components of the cutaneous basement membrane, are 
defined immunologically by autoantibodies in the sera of patients 
with the supepidermal blistering disease BP. Biochemical and mo-
lecular biologic studies have shown that BP antigen (BPAG) is 
composed of two major hemidesmosome-associated proteins, the 
230-kDa antigen (BPAG1) and the 180-KDa antigen (BPAG2). 
Recent immunoelectron microscopic studies showed that BPAG 1 is 
an intracellular protein, whereas BPAG2 is a transmembrane pro-
tein and can be detected on the cell surface (Ishiko et al:] Clitl Invest 
91:1608 - 1615,1993). 
Rather than immunoelectron microscopy, which is a demanding 
technique and is available only in a few laboratories, antigenic map-
ping using skin "split" after prolonged incubation in buffers con-
taining 1 M NaCI has been used extensively to characterize the 
binding site of BP autoantibody, especially to distinguish patients 
with other blistering disorders such as epidermolysis bullosa acquis-
ita and bullous systemic lupus erythematosus. When human skin is 
incubated with 1 M NaCI, the basement Inembrane splits at the 
lamina lucida. Most BP sera bind only to the epidermal side of this 
split skin, but some sera from patients classified as having BP bind to 
the dermal side as well. The relationship between autoantibodies 
identifying BPAG1 or BPAG2 or both and their binding sites on 1 
M NaCI split skin has not been elucidated. In this issue, Yuko 
Onodera and her colleagues from K~io University in Tokyo (p. 
686) studIed more than 100 BP sera by Immunofluorescence on split 
skin, immunoblotting, and immunoelectron microscropy. Their 
studies show that sera containing autoantibodies against BP AG 1 Or 
BPAG2 or both antigens always decorate the epidermal side of split 
skin and never bind solely to the dermal side. They also demonstrate 
that autoantibodies against BPAG2, but not those against BPAG 1, 
bind both epidermal and dermal sides of split skin. They speculate 
that although BP AG 1 is always found on the epidermal side in split 
skin, BPAG2 may be present on both epidermal and dermal sides. 
These results should provide a better conceptual basis for the inter-
pretation of the binding pattern of pemphigoid serum on split skin. 
Abnormal Keratin Filaments in Epidermolytic Hyperkeratosis In Vitro 
Epidermolytic hyperkeratosis (EHK), an autosomal dominant skin 
disorder characterized by erythematous blisters early in life and 
hyperkeratosis later, shows characteristic ultrastructural abnormali-
ties in the epidermis. The most prominent feature is collapse of the 
keratin intermediate filament network composed of keratins 1 and 
10 (KI and KI0), which produces clumped and perinuclear tonofi-
laments on electron microscopy. Data from linkage studies are in 
agreement with nucleotide sequence analyses ofDN A strongly sug-
gesting that point mutations in the K1 or KI0 genes are responsible 
for the EHK phenotype. In this issue, Huber et al (p. 691) describe 
the cytoskeleton of keratinocytes cultured from two EHK patients 
with mutations in the K10 1A rod domain. When they proliferate, 
the EHK keratinocytes express K5 and K14 and have a normal 
cytoskeleton. When they differentiate, however, and express Kl 
and KlO, the morphology becomes abnormal. The authors show 
that the mRNA expressed in these cells reflects the mutations found 
in the patient's genomic DNA, and immunofluorescence with anti-
K 1 and anti-Kl 0 antibodies shows changes similar to those found irt 
EHK keratinocytes ill villo. These results indicate that changes in the 
rod domain 1A ofK10 are responsible for morphologic changes ill 
vitro comparable to those found in ViIlO, a finding similar to that irt 
epidermolysis bullosa simplex, in which mutations in the rod do-
mains of K5 and K14 have been described (see the review by Fuchs 
E:] Invest DermatoI99:671-674, 1992). Although two K10 point 
mutations in EHK patients have now been clearly linked to the 
collapse of the intermediate filament network, it will be important 
to determine how the mutation produces blisters in infancy and 
hyperkeratosis later in life. 
Identification of the Risk of Melanoma 
Moles, skin type and hair color, and sunburns in childhood have 
been proposed as risk factors for melanoma, but the role of moles is 
controversial. R. Mackie et al have calculated risk based on total 
number of nevi, the number of atypical melanocytic nevi, a freck-
ling tendency, and episodes of sunburn (Lancet 11:487 - 490, 1989). 
In this issue, Garbe et al (p. 695) describe a prospective multicenter 
study of 513 newly diagnosed melanoma patients and 498 controls. 
All subjects were examined by dermatologists for common and 
atypical nevi, actinic lentigines, other types of pigmented lesions, 
pigmentation, and solar damage. Interviews were used to determine 
sun exposure, sunburns, and other possible risk factors. Multivariate 
regression analysis revealed six independent factors with significant 
impact on risk: common melanocytic nevi, atypical melanocytic 
nevi, actinic lentigines, hair color, skin type, and reported growth of 
melanocytic nevi. Sunburn in childhood, found to be a significant 
risk factor by bivariate analysis, was excluded from the independent 
factors after adjustment for other risk factors. The most important 
factors were the total number of common melanocytic nevi and the 
number of atypical melanocytic nevi, which showed 7.6-fold and 
6.1-fold risks for developing melanoma. The increase in risk was 
nearly linear with increasing number of common melanocytic nevi. 
Only a slightly increased risk increase was found for one to four 
atypical melanocytic nevi, but a marked increase was found for five 
or more such nevi. These findings suggest that clinical recognition 
of atypical nevi without histologic examination can identify pa-
tients with increased risk for melanoma and that a threshold value 
exists for defining the syndrome of atypical nevi. High numbers of 
common melanocytic nevi, presence of atypical melanocytic nevi , 
and presence of actinic lentigines distinguished subgroups with rel-
ative risks ranging from 1 to 121. With these results, and using the 
proposed risk assessment scheme, the authors feel that dermatolo-
gists should be able to recognize persons at increased risk for mela-
noma by examination alone. 
